Discontinue immediately at the 1st appearance of a skin rash or any other sign of hypersensitivity; if patient experiences peripheral neuropathy symptoms. Patient w/ known risk factors for QT interval prolongation eg, congenital long QT syndrome, concomitant use of QT interval prolonging drugs (eg, class IA & III antiarrhythmics, TCAs, antidepressants, macrolides & antipsychotics), uncorrected electrolyte imbalance, elderly, cardiac disease (eg, heart failure, MI, bradycardia). Patient w/ known history of myasthenia gravis; known or suspected CNS disorder that may predispose to seizures or lower seizure threshold. May increase intracranial pressure & CNS stimulation (following the 1st dose) which may lead to tremors, restlessness, anxiety, lightheadedness, confusion, hallucinations, paranoia, depression, nightmares, insomnia & rarely, suicidal thoughts or acts. Consider diagnosis of pseudomembranous colitis in patients who present diarrhea following treatment. Discontinue if patient experiences pain, inflammation, or tendon rupture. Levofloxacin inj should only be administered by slow IV infusion over a period of 60 or 90 min depending on the dosage. Maintain adequate hydration. Avoid excessive exposure to sunlight. Monitor blood glucose of diabetics receiving concomitant treatment w/ an oral hypoglycemic (eg, glyburide, glibenclamide) or w/ insulin. Periodic assessment of organ system functions, including renal, hepatic & hematopoietic during therapy. May cause neurologic adverse effects (eg, dizziness, lightheadedness) that may impair ability to drive or operate machinery or engage in other activities requiring mental alertness & coordination. Dosage adjustment is necessary for patients w/ impaired renal function (CrCl <50 mL/min). Pregnancy & lactation. Childn <18 yr. Elderly.